- HK$84.10bn
- HK$79.10bn
- CNY3.06bn
Alphamab Oncology leads slide in HK pharma stocks on Trump's plan to trim medicine prices
Summit Therapeutics closes 36% lower after interim data for cancer drug
Brief: Akeso Says FDA Approved Anniko (Penpulimab-Kcqx, Pd-1) In Two Indications
Summit Therapeutics gains as lung cancer drug succeeds in second study in China
Brief: Akeso Says NMPA Approved NDA Of Ebdarokimab, Il-12/Il-23
Brief: Akeso Ebdarokimab Approved In China For Moderate - To - Severe Plaque Psoriasis
Brief: Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA
Brief: Akeso Says NMPA Approved SNDA Of (Cadonilimab, Pd-1/Ctla-4) In Combination With Chemotherapy
Summit shares hit record high as cancer drug tops Keytruda in China trial (updated)
Refile: Summit shares surge as cancer drug tops Keytruda in head-to-head study
Brief: Akeso Posts Loss RMB249.3 Million For Six Months
Brief: Akeso Posts H1 Gross Profit RMB 943.2 Million
Brief: Akeso Says Ak112-303/Harmoni-2 Was Accepted As LBA
Brief: Akeso Says NMPA Accepted Supplemental New Drug Application For Ivonescimab
Brief: Akeso Inc Announces Appointment Of Bing C. Wang As CFO
Brief: Akeso Says Zhang Peng Appointed As Executive Director
China's Akeso hits near 3-year peak on Summit Therapeutics therapy success in study
Summit Therapeutics cancer therapy succeeds in late-stage China study (updated)
Brief: Akeso Says (Ivonescimab Injection) Obtained Nmpa's Marketing Approval In China